Key facts
- It has raised $2.1M; the latest was Seed Round ($2.0M) in Mar 2026.
- Notable investors include Skin Angels.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Stratum Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Stratum Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stratum Biosciences
Developer of a dermatology research platform designed to accelerate the discovery of active ingredients and formulations for skin health. The company offers an AI-driven platform leveraging real tissue data and a pipeline of proprietary compounds targeting skin conditions, enabling skincare companies and research organizations to develop effective treatments for various dermatological needs.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 11
- Website
- stratumbio.com/
- Ownership
- Privately Held (backing)
Stratum Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stratum Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stratum Biosciences in its N-PORT filings yet. We sweep new filings monthly.